Evidence map›Paper›PMID 41608548›Full record

ReviewDermatology research and practice2026

Fibroblast Dynamics in Keloid Pathogenesis: Unraveling Cellular Crosstalk and Novel Therapeutic Targets.

Ziad Alkouz, Ala'a Al Suwait, Lian Zhang, Rehab Alhejairi, Freddy Gahimbare, Mahmoud Qalalwa, Bin Yang

Abstract readReview
In one paragraph

Review in Dermatology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ziad AlkouzDermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
Ala'a Al SuwaitDermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
Lian ZhangDermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
Rehab AlhejairiDermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.ORCID https://orcid.org/0009-0007-3652-0787
Freddy GahimbareDermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
Mahmoud QalalwaDermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
Bin YangDermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.ORCID https://orcid.org/0000-0002-7155-6079

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Keloid scars represent a complex fibroproliferative disorder characterized by abnormal wound healing and excessive collagen deposition. Central to keloid pathogenesis are dynamic fibroblast populations that undergo extensive phenotypic transitions, including heterogeneous subpopulation differentiation, enhanced migration, myofibroblast transdifferentiation, and sustained activation states. This review examines fibroblast dynamics as the central orchestrator of keloid formation, analyzing how these cells interact with keratinocytes, immune cells, endothelial cells, and melanocytes to drive pathological scarring. We focus on key signaling pathways that directly regulate fibroblast function, including TGF-β/Smad, VEGF, Wnt, and emerging regulators such as miR-3606-3p that integrate multiple fibrotic cascades. Current therapeutic approaches show variable efficacy, with surgical excision alone resulting in 45%-100% recurrence rates, while combination therapies incorporating radiation, intralesional injections, and novel molecular targets achieve improved outcomes. Emerging strategies include COX-2 inhibition for dual antiproliferative and proapoptotic effects on keloid fibroblasts, stem cell therapies, and precision medicine approaches based on molecular profiling. Through deeper understanding of fibroblast dynamics and their regulatory networks, more effective therapeutic strategies can be developed to improve patient outcomes and quality of life.

Indexed as

cellular heterogeneityfibroblast dynamicskeloid fibroblastsprecision medicineTGF-β signalingtherapeutic targets

Identifiers

PMID41608548
PMCPMC12836040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.